PCI CONGRATULATES ELI LILLY AND NOVARTIS FOR COMPLIANCE PACKAGE OF THE YEAR AWARDS

Philadelphia, PA – April 13, 2015 - Packaging Coordinators, Inc. (PCI) congratulates Eli Lilly and Novartis for their recent awards in the Healthcare Compliance Packaging Council’s 2014 Compliance Package of the Year awards competition. HCPC recognized Eli Lilly as the 1st Runner Up for the Strattera Physician Sample Pack at the RxAdherence conference on patient adherence in Florham Park, NJ on March 31st, while also recognizing Novartis for Exforge HCT as 2nd Runner Up in the competition. Eli Lilly Strattera is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 and older, teens, and adults. Submitted by PCI on behalf of Eli Lilly, the Strattera Physician Sample Pack utilizes the MWV DosepakTM design in titrating patients through their drug regimen, progressing them to the target dose. The package graphics feature distinctive varied color coding for the calendarized dosing format, identifying the starting dose of 18mg and continuing for the first five days of therapy, progressing to 25mg for the following five days, 40mg for the next five, and reaching 60mg, identified on the pack as the “Target Dose”, for the remaining 30 days of the 45 day therapy contained in the pack. Other versions of the titration dosing utilize a 10 / 18 / 25 / 40mg format, 25 / 40 / 60 / 80mg depending on the weight of the patient. Each strength combination is distinguished by a unique color configuration and identifies the recommended weight guidelines for the therapy. In further supporting patient compliance, the Strattera design includes a multipanel label that identifies dosing instructions including tips to avoid side effects and identifying optimal daily timing for doses, along with its boxed warning and safety information. Patients are instructed to work with their physician to set goals for treatment, and prompted in the package’s calendarized dosing schedule to “begin evaluating symptoms” at Day 30. The multipanel label also includes patient education facts regarding ADHD as well as information directing patients to a supporting website to seek further information, download and establish the goal setting progress tracker tool resource, download a discussion guide resource for patient-doctor interaction, as well as information for prescription savings for the patient. A patient information leaflet is also included for the patient in the cover panel of the Strattera Sample Pack. Novartis Exforge HCT (amlodipine, valsartan, hydrocholorothiazide) is indicated for the treatment of high blood pressure. Submitted by PCI on behalf of Novartis, the Exforge HCT blister package utilizes the MWV Shellpak Renew child resistant design to support patients in taking their daily medication. The package graphics highlight the calendarized format, helping support patients to follow their regimen as prescribed by their doctor. On the primary blister unit colorful graphics help to identify the starting dose, each daily dose, and reminds patients when the time to refill the prescription is approaching. The exterior packaging graphics highlight the opening instructions for the innovative push/pull child resistant feature, along with patient instructions for identifying their starting dose. Included with the Exforge HCT package are additional adherence tools such as a patient savings card to support patients with script fills as well as suggestions for the patient to visit the website and join the Get On Track program. The website contains disease state information, co-pay assistance and healthcare tips for patients with high blood pressure including recipes and health insights. Also included with the Exforge HCT package is the prescribing information leaflet. PCI has a distinguished history in the design competition. PCI has supported winning packages in previous years, most recently including the Noven Therapeutics Brisdelle design recognized as Compliance Package of the Year in 2014 and Depomed’s Gralise as 1st Runner Up. About PCI The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information please visit www.pciservices.com or follow us on Twitter at @PCI_Social. Contact Justin Schroeder, Executive Director - Marketing, Business Development and Design [email protected], (815) 484-8973

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.